Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
1.830
0.00 (0.00%)
At close: May 11, 2026, 4:00 PM EDT
1.825
-0.005 (-0.27%)
Pre-market: May 12, 2026, 8:11 AM EDT

Compass Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
--0.85---
Gross Profit
--0.85---
Selling, General & Admin
18.8733.7430.2712.2411.6610.93
Research & Development
56.3111.9484.6838.123070.96
Total Operating Expenses
75.17145.68114.9550.3641.6681.88
Operating Income
-75.17-145.68-114.1-50.36-41.66-81.88
Interest Income
5.816.357.25---
Other Non-Operating Income (Expense)
3.466.357.257.872.43-0.3
Total Non-Operating Income (Expense)
712.714.57.872.43-0.3
Pretax Income
-68.17-132.98-99.6-42.49-39.23-82.18
Net Income
-68.17-66.49-49.38-42.49-39.23-82.18
Net Income to Common
-68.17-66.49-49.38-42.49-39.23-82.18
Shares Outstanding (Basic)
17015813712710563
Shares Outstanding (Diluted)
17015813712710563
Shares Change (YoY)
23.07%14.78%8.15%20.76%67.31%104.28%
EPS (Basic)
-0.41-0.42-0.36-0.33-0.37-1.31
EPS (Diluted)
-0.41-0.42-0.36-0.33-0.37-1.31
Shares Outstanding
180.09178.32137.82127.67126.3100.83
Free Cash Flow
-53.29-49.17-44.9-40.65-34.34-21.23
Free Cash Flow Per Share
-0.31-0.31-0.33-0.32-0.33-0.34
Gross Margin
--100.00%---
Operating Margin
---13423.50%---
Profit Margin
---5808.82%---
FCF Margin
---5282.24%---
EBITDA
-75.02-145.4-113.51-49.66-40.87-81.32
EBITDA Margin
---13354.20%---
EBIT
-75.17-145.68-114.1-50.36-41.66-81.88
EBIT Margin
---13423.50%---
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q